You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1 pathway inhibitors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With

Completed
  • Metastatic Colorectal Adenocarcinoma
  • Changsha, Hunan, China
    Hunan Cancer hospital
Sep 2, 2023

Colorectal Liver Metastases Trial in Nanjing (Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors)

Recruiting
  • Colorectal Liver Metastases
  • Radiation: High- and Low-dose radiotherapy
  • PD-1 Inhibitors
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Sep 13, 2023

Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Lung Cancer
  • Centipeda minima+PD-1/PD-L1 inhibitor
  • PD-1/PD-L1 inhibitor
  • (no location specified)
Feb 17, 2023

Gastric Adenocarcinoma Trial (cadonilimab combined +paclitaxel (albumin-bound))

Not yet recruiting
  • Gastric Adenocarcinoma
  • cadonilimab combined +paclitaxel (albumin-bound)
  • (no location specified)
Nov 1, 2023

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Carotid Artery Plaque, Pd-1 Inhibitors Trial in Hangzhou (PD-1 inhibitor)

Recruiting
  • Carotid Artery Plaque
  • Pd-1 Inhibitors
  • PD-1 inhibitor
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital of Zhejiang University, School of
Sep 17, 2022

Rectal Tumors Trial in Nanning (Tislelizumab, Capecitabine, Oxaliplatin)

Recruiting
  • Rectal Neoplasms
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Aug 27, 2023

Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer Recurrent
  • Toripalimab, Anlotinib and Chemotherapy
  • (no location specified)
Apr 24, 2023

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in

Recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Brain Metastases
  • Radiotherapy combined with PD-1 inhibitors
  • Changsha, Hunan, China
    Xiangya Hospital, Central South University
Nov 27, 2022

NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy Trial in Chengdu (Low Dose Radiotherapy, stereotactic body

Not yet recruiting
  • NSCLC
  • +3 more
  • Low Dose Radiotherapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Nov 11, 2022

/or PD-1 Inhibitors for Unresectable Intrahepatic

Completed
  • Intrahepatic Cholangiocarcinoma
  • hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 7, 2022

Metastatic Extracranial Malignant Solid Tumor, Radiotherapy, Immune Checkpoint Blockade Trial in Shantou (Intestinal Low Dose

Not yet recruiting
  • Metastatic Extracranial Malignant Solid Neoplasm
  • +3 more
  • Intestinal Low Dose Radiotherapy-1Gy
  • +3 more
  • Shantou, Guangdong, China
    Cancer Hospital, Shantou University Medical College
Oct 7, 2023

the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma Trial in Shanghai

Not yet recruiting
  • the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma
  • Radiation
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cencer Center
Aug 10, 2022

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in

Recruiting
  • Malignant Pleural Mesothelioma, Advanced
  • Oncolytic Adenovirus H101
  • Programmed death receptor-1 inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical Unversity Second Hospital
Sep 2, 2023

Biliary Tract Cancer Trial in Changchun (Lenvatinib, PD-1 inhibitors)

Recruiting
  • Biliary Tract Cancer
  • Changchun, Jilin, China
    Liu Bo
Aug 18, 2022

Gastric Cancer Trial (Fruquintinib+PD-1)

Not yet recruiting
  • Gastric Cancer
  • (no location specified)
Feb 1, 2023

Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)

Recruiting
  • Colorectal Cancer
  • Microsatellite Instability High
  • PD-1 inhibitor plus VEGF inhibitors
  • Guangzhou, Guangdong, China
    651 Dongfeng Road East
May 27, 2022

Non Small Cell Lung Cancer Trial in Changsha (Anlotinib Plus Penpulimab)

Recruiting
  • Non Small Cell Lung Cancer
  • Anlotinib Plus Penpulimab
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 17, 2022

Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors Trial in Zhengzhou (IBI110+Sintilimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • PD-1 Inhibitors
  • Zhengzhou, Henan, China
    Feng Wang
Oct 9, 2023

Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Tumors Trial in Guangzhou (Pemigatinib, PD-1 Inhibitors)

Recruiting
  • Carcinoma
  • +4 more
  • Guangzhou, Guangdong, China
    Lei Zhang
Jun 21, 2023

Objective Response Rate Trial in Wuhan (GM-CSF)

Recruiting
  • Objective Response Rate
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Feb 25, 2023

NSCLC Trial in Rotterdam (Nutritional intervention, Immunotherapy)

Recruiting
  • Non-small Cell Lung Cancer
  • Rotterdam, Netherlands
    Erasmus MC
Jun 5, 2023

Advanced or Metastatic Urothelium Cancer Trial in Beijing (MRG002, Docetaxel Injection, Paclitaxel Injection)

Not yet recruiting
  • Advanced or Metastatic Urothelium Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Feb 22, 2023